Skip to main content

Table 2 Number of events and rates of included randomised controlled trials

From: Cardiovascular and mortality events in type 2 diabetes cardiovascular outcomes trials: a systematic review with trend analysis

Randomised controlled trial (RCT) All-cause mortality Cardiovascular disease mortality Major adverse cardiovascular eventsa Total myocardial infarction Nonfatal myocardial infarction Total stroke Nonfatal stroke
n Rate n Rate n Rate n Rate n Rate n Rate n Rate
UGDP 21 14.6 10 7.0 – – – – – – – – – –
UKPDS 33 213 18.9 – – – – 186 17.4 101 9.5 55 5.0 44 4.0
DCGP 147 48.0 – – – – 75 27.3 – – 50 17.4 – –
STENO-2 15 24.0 7 11.2 – – – – 17 27.2 – – 20 32.1
JDCS 43 5.4 – – – – – – – – 75 9.5 – –
VADT 95 18.9 29 5.8 – – 78 15.5 – – 36 7.2 – –
PROactive 186 24.5 – – – – – – 144 19.0 107 14.1 – –
LOOK AHEAD 202 8.6 57 2.4 283 12.5 191 8.4 183 8.0 80 3.4 – –
RECORD 157 12.8 71 5.8 165 13.5 56 4.6 – – 63 5.1 – –
ADVANCE 533 19.1 – – 590 21.2 337 12.1 – – 246 8.8 – –
ACCORD 203 11.4 94 5.6 371 22.9 – – 235 14.5 – – 61 3.7
ADDITION 92 12.5 – – – – – – – – – – – –
HEART2D 102 33.9 86 28.6 – – 126 41.9 103 34.2 37 12.3 35 11.6
ORIGIN 965 26.0 576 15.5 1013 28.5 326 9.0 – – 319 8.8 – –
TECOS 537 24.5 366 16.7 746 36.2 316 15.1 – – 183 8.7 – –
TOSCA 105 7.5 – – – – – – 45 3.0 – – 40 2.5
EXAMINE 173 43.1 130 32.4 316 78.6 – – – – – – – –
CANVAS 307 19.5 201 12.8 496 31.5 198 12.6 183 11.6 151 9.6 132 8.4
SAVOR-TIMI 378 21.0 260 14.5 609 36.0 278 17.0 – – – – – –
LEADER 447 25.0 278 16.0 694 39.0 339 19.0 317 18.0 199 11.0 177 10.0
ALECARDIO 138 19.1 98 13.6 360 49.9 – – 239 33.1 – – 50 6.9
ELIXA 223 33.0 158 24.0 – – 261 41.0 – – 60 9.0 – –
EMPAREG 194 28.6 137 20.2 282 43.9 – – – – 69 10.5 60 9.1
EXSCEL 584 23.0 383 15.0 905 40.0 493 21.0 – – 218 9.0 – –
SUSTAIN-6 60 17.6 46 13.5 146 44.0 – – 64 19.2 – – 44 13.1
DEVOTE 423 28.0 278 18.4 681 45.0 – – 313 23.7 – – 150 10.7
  1. Trials are listed by starting calendar year (older to newer) and number of participants (largest to smallest); their references are reported in the supplementary material. Data shown for control arm (except DEVOTE, TOSCA, HEART2D where arms were combined)
  2. n number of events; rate are per 1000 person-years
  3. a3-Point major adverse cardiovascular events: cardiovascular death, nonfatal myocardial infarction, nonfatal stroke (details are reported in Supplementary Table S3)
Back to article page